Antifungal activity of SCY-078 and standard antifungal agents against 178 clinical isolates of resistant and susceptible candida species

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 11, 2017, Pages

  Schell, Wiley A ^a   Jones, A M ^b   Borroto Esoda, Katyna ^c   Alexander, Barbara D ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^c Scynexis   (United States)

Author keywords

Antifungal agents; Antifungal resistance; Candida

Indexed keywords

ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; MICAFUNGIN; SCY 078; UNCLASSIFIED DRUG; VORICONAZOLE; GLYCOSIDE; MK-3118; TRITERPENE;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BROTH DILUTION; CANDIDA; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CLAVISPORA LUSITANIAE; FUNGUS ISOLATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PICHIA KUDRIAVZEVII; PRIORITY JOURNAL; ANTIFUNGAL RESISTANCE; DRUG EFFECT; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST;

ANTIFUNGAL AGENTS; CANDIDA; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; GLYCOSIDES; HUMANS; MICROBIAL SENSITIVITY TESTS; TRITERPENES; VORICONAZOLE;

EID: 85032501559     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01102-17     Document Type: Article

References (24)

1. Dodds Ashley E, Drew R, Johnson M, Danna R, Dabrowski D, Walker V, Prasad M, Alexander B, Papadopoulos G, Perfect J. 2012. Cost of invasive fungal infections in the era of new diagnostics and expanded treatment options. Pharmacotherapy 32:890–901. https://doi.org/10.1002/j.1875-9114.2012.01124.
2. Messer SA, Jones RN, Fritsche TR. 2006. International surveillance of Candida spp. and Aspergillus spp.: report from the SENTRY antimicrobial surveillance programs (2003). J Clin Microbiol 44:1782–1787. https://doi.org/10.1128/JCM.44.5.1782-1787.2006.
3. Costa-de-Oliveira S, Pina-Vaz C, Mendonça D, Gonçalves Rodrigues A. 2008. A first Portuguese epidemiological survey of fungaemia in a university hospital. Eur J Clin Microbiol Infect Dis 27:365–374. https://doi.org/10.1007/s10096-007-0448-4.
4. Pfaller M, Neofyots D, Diekema D, Azie N, Meier-Kriesche HU, Quan SP, Horn D. 2012. Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance®) registry, 2004–2008. Diagn Microbiol Infect Dis 74:323–331. https://doi.org/10.1016/j.diagmicrobio.2012.10.003.
5. Zilberberg MD, Shorr AF, Kollef MH. 2008. Growth and geographic variation in hospitalizations with resistant infections, United States, 2000–2005. Emerg Infect Dis 14:1756–1758. https://doi.org/10.3201/eid1411.080337.
6. Zilberberg MD, Shorr AF, Kollef MH. 2008. Secular trends in candidemia-related hospitalization in the United States, 2000–2005. Infect Control Hosp Epidemiol 29:978–980. https://doi.org/10.1086/591033.
7. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, Moreno R, Lipman J, Gomersall C, Sakr Y, Reinhart K. 2009. International study of the prevalence and outcomes of infection in intensive care units. JAMA 302:2323–2329. https://doi.org/10.1001/jama.2009.1754.
8. Hidron AI, Edwards JR, Patel J, Horan TC, Sievert DM, Pollock DA, Fridkin SK. 2008. Antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007. Infect Control Hosp Epidemiol 29:996–1011. https://doi.org/10.1086/591861.
9. Pfaller MA, Diekema DJ. 2007. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 20:133–163. https:// doi.org/10.1128/CMR.00029-06.
10. Walker SS, Xu Y, Triantafyllou I, Waldman MF, Mendrick C, Brown N, Mann P, Chau A, Patel R, Bauman N, Norris C, Antonacci B, Gurnani M, Cacciapuoti A, McNicholas PM, Wainhaus S, Herr RJ, Kuang R, Aslanian RG, Ting PC, Black TA. 2011. Discovery of a novel class of orally active antifungal -1,3-D-glucan synthase inhibitors. Antimicrob Agents Chemother 55:5099–6106. https://doi.org/10.1128/AAC.00432-11.
11. Pfaller MA, Messer SA, Motyl MR, Jones RN, Castanheira M. 2013. Activity of MK-3118, a new oral glucan synthase inhibitor, tested against Candida spp. by two international methods (CLSI and EUCAST). J Antimicrob Chemother 68:858 – 863. https://doi.org/10.1093/jac/dks466.
12. Jiminez-Ortigosa C, Paderu P, Motyl MR, Perlin DS. 2014. Enfumafungin derivative MK-1138 shows increased in vitro potency against clinical echinocandin-resistant Candida species and Aspergillus species isolates. Antimicrob Agents Chemother 58:1248–1251. https://doi.org/10.1128/AAC.02145-13.
13. Lepak AJ, Marchillo K, Andes DR. 2015. Pharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078 (MK-3118), using an in vivo murine invasive candidiasis model. Antimicrob Agents Chemother 59:1265–1272. https://doi.org/10.1128/AAC.04445-14.
14. Alexander BD, Johnson MD, Pfeiffer CD, Jiminez-Ortigosa C, Catania J, Booker R, Castanheira M, Messer SA, Perlin DS, Pfaller MA. 2013. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis 56:1724–1732. https://doi.org/10.1093/cid/cit136.
15. Pfeiffer CD, Garcia-Effron G, Zaas AK, Perlin DS, Alexander BD. 2010. Breakthrough invasive candidiasis in patients on micafungin. J Clin Microbiol 48:2373–2380. https://doi.org/10.1128/JCM.02390-09.
16. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard—3rd ed. M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
17. Clinical and Laboratory Standards Institute. 2012. Reference method for broth dilution antifungal susceptibility testing of yeasts; 4th informational supplement. M27-S4. Clinical and Laboratory Standards Institute, Wayne, PA.
18. Garcia-Effron G, Park S, Perlin DS. 2009. Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. Antimicrob Agents Chemother 53:112–122. https://doi.org/10.1128/AAC.01162-08.
19. Garcia-Effron G, Lee S, Park S, Cleary JD, Perlin DS. 2009. Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3--D-glucan synthase: implication for the existing susceptibility breakpoint. Antimicrob Agents Chemother 53:3690–3699. https://doi.org/10.1128/AAC.00443-09.
20. Dudiuk C, Macedo D, Leonardelli F, Theill L, Cabeza MS, Gamarra S, Garcia-Effron G. 2017. Molecular confirmation of the relationship between Candida guilliermondii Fks1p naturally occurring amino acid substitutions and its intrinsic reduced echinocandin susceptibility. Antimicrob Agents Chemother 61:e02644-16. https://doi.org/10.1128/AAC.02644-16.
21. Dudiuk C, Gamarra S, Leonardeli F, Jimenez-Ortigosa C, Vitale RG, Afeltra J, Perlin DS, Garcia-Effron G. 2014. Set of classical PCRs for detection of mutations in Candida glabrata FKS genes linked with echinocandin resistance. J Clin Microbiol 52:2609–2614. https://doi.org/10.1128/JCM .01038-14.
22. Clinical and Laboratory Standards Institute. 2017. Epidemiological cutoff values for antifungal susceptibility testing. M59. Clinical and Laboratory Standards Institute, Wayne, PA.
23. Garcia-Effron G, Katiyar SK, Park S, Edlind TD, Perlin DS. 2008. A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. Antimicrob Agents Chemother 52: 2305–2312. https://doi.org/10.1128/AAC.00262-08.
24. Wring SA, Randolph R, Park SH, Abruzzo G, Chen Q, Flattery A, Garrett G, Peel M, Outcalt R, Powell K, Trucksis M, Angulo D, Borroto-Esoda K. 2017. Preclinical pharmacokinetics and pharmacodynamic target of SCY-078, a first-in-class orally active antifungal glucan synthesis inhibitor, in murine models of disseminated candidiasis. Antimicrob Agents Chemother 61: e02068-16. https://doi.org/10.1128/AAC.02068-16.